

Disclosure of Value Transfers

Methodological Note

Country	ESPAÑA	
Entity Name	FRESENIUS KABI ESPAÑA, S.A.	
Legal Basis for Disclosure	Código de conducta sobre interacciones con la comunidad sanitaria – Asociación Española de Medicamentos Genéricos (AESEG).	
Reporting Period	2024	
Currency of	All values are disclosed in	
disclosed values	⊠ EUR	
	□ [local currency, if required]	
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to generics medicinal products.	
Value identification and Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient and booked in the respective reporting period.	
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.	
Data disclosed	All values are disclosed for	
for	☐ Recipients which have been engaged by entity	
	☑ Recipients which have their residence in the country	
VAT and other taxes	All amounts are disclosed without VAT or another taxes.	
Disclosure location:	https://www.fresenius-kabi.com/es/compromiso-social-sostenibilidad/etica-transparencia	

Annex Document No.: Date:

Version: 00 Page:

Date of Publication: 30/06/2025



Disclosure of Value Transfers

Value category: "Meetings, educational support and site visits of HCPs"	The company discloses value transfers in this category as per Option 2 of the AESEG Transparency Requirements (as per section 7.2.4,b): Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:
	 Sponsorship for attending a third party organized congress: name of congress,
	- aggregated amount spent for the congress, including the
	- number of Healthcare Professionals financially supported to attend
	• Site visits: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
	• Company organized meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	Fees paid in connection with research & development activities or market research have not been disclosed.

Annex Document No.: Date: Version: Page: 2 of 2 30/06/2025

Date of Publication: